Latest stories on MESO
Mesoblast price target raised to $39 from $35 at Piper Sandler
The Fly61 · neutralanalyst
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Mesoblast Reports Substantial Revenue Growth to US$120M
GlobeNewswire67 · bullishearnings
Mesoblast Reports Substantial Revenue Growth to US$120M
StockTitan67 · bullishearnings
Mesoblast H2 Earnings Call Highlights
Yahoo Finance58 · neutralearnings
Mesoblast Q2 Earnings Preview
Seeking Alpha50 · neutralearnings
Mesoblast Financial Results and Corporate Update Webcast
Business Insider50 · neutralearnings
Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire50 · neutralgeneral
Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment
InvestorsHub63 · neutralproduct/pr
Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial
The Fly59 · neutralproduct/pr
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Business Insider67 · bullishproduct/pr
Mesoblast Limited 2026 Q4 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
TipRanks63 · neutralproduct/pr
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
StockTitan59 · neutralearnings
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain | MESO Stock News
StockTitan58 · neutralproduct/pr
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Seeking Alpha67 · bullishproduct/pr
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Business Insider55 · neutralproduct/pr
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 | MESO Stock News
StockTitan59 · neutralearnings
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility | MESO Stock News
StockTitan59 · neutralgeneral
Meso Numismatics reports Q1 results
Seeking Alpha50 · neutralearnings
Mesoblast Showcases Profitable Ryoncil Launch and Expanding Cell Therapy Pipeline in June 2026 CEO Presentation
TipRanks67 · bullishproduct/pr
Mesoblast Limited (MESO) Presents at ASX CEO Connect June 2026 - Slideshow
Seeking Alpha50 · neutralgeneral